The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

Follow the latest RSV cases news stories and headlines. Get breaking news alerts when you download the ABC News App and subscribe to RSV cases notifications.

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants.

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.

The Food and Drug Administration (FDA) has expanded the approval of mResvia (respiratory syncytial virus [RSV] vaccine) to include active immunization in individuals 18 through 59 years of age who ...

The simplicity of the new monoclonal Enflonsia could give it an advantage over AstraZeneca’s Beyfortus Enflonsia, a monoclonal antibody for RSV, is approved for use in children under 12 months ...

In the U.S., an estimated 58,000–80,000 children younger than five years are hospitalized due to RSV each year, according to the U.S. Centers for Disease Control and Prevention.

Zucker asked whether ACIP's RSV work group had discussed shared decision making. ACIP chair Helen Keipp Talbot, MD, who is also a member of the work group, said that they had. "There was a huge ...